Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm-MedSci.cn

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm

Zeidner, JF; Lee, DJ; Fine, G; Wang, ES; Bhatt, VR; Dalovisio, A; Montesinos, P; Kolibaba, KS; Anthony, SP; Bearss, DJ; Smith, BD

BLOOD, 2020; 136 ():

科室
- - 订阅+
  - 更多科室
工具
服务